Literature DB >> 22889670

Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects.

Chera L Maarouf1, Thomas G Beach, Charles H Adler, Holly A Shill, Marwan N Sabbagh, Terence Wu, Douglas G Walker, Tyler A Kokjohn, Alex E Roher.   

Abstract

OBJECTIVES: Parkinson's disease (PD) afflicts approximately 1-2% of the population over 50 years of age. No cures or effective modifying treatments exist and clinical diagnosis is currently confounded by a lack of definitive biomarkers. We sought to discover potential biomarkers in the cerebrospinal fluid (CSF) of neuropathologically confirmed PD cases.
METHODS: We compared postmortem ventricular CSF (V-CSF) from PD and normal control (NC) subjects using two-dimensional difference gel electrophoresis (2D-DIGE). Spots exhibiting a 1·5-fold or greater difference in volume between PD patients and controls were excised from the two-dimensional gels, subjected to tryptic digestion and identification of peptides assigned using mass spectrometric/data bank correlation methods.
RESULTS: Employing this strategy six molecules: fibrinogen, transthyretin, apolipoprotein E, clusterin, apolipoprotein A-1, and glutathione-S-transferase-Pi, were found to be different between PD and NC populations. DISCUSSION: These molecules have been implicated in PD pathogenesis. Combining biomarker data from multiple laboratories may create a consensus panel of proteins that may serve as a diagnostic tool for this neurodegenerative disorder.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22889670      PMCID: PMC3681206          DOI: 10.1179/1743132812Y.0000000063

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  53 in total

1.  Protein profiling of Guillain-Barrè syndrome cerebrospinal fluid by two-dimensional electrophoresis and mass spectrometry.

Authors:  Simona D'Aguanno; Diego Franciotta; Santina Lupisella; Alessandra Barassi; Damiana Pieragostino; Alessandra Lugaresi; Diego Centonze; Gianlodovico Melzi D'Eril; Sergio Bernardini; Giorgio Federici; Andrea Urbani
Journal:  Neurosci Lett       Date:  2010-08-27       Impact factor: 3.046

2.  Use of haptoglobin and transthyretin as potential biomarkers for the preclinical diagnosis of Parkinson's disease.

Authors:  S Argüelles; J L Venero; S García-Rodriguez; M Tomas-Camardiel; A Ayala; J Cano; A Machado
Journal:  Neurochem Int       Date:  2010-06-08       Impact factor: 3.921

3.  Incidental Lewy body disease: clinical comparison to a control cohort.

Authors:  Charles H Adler; Donald J Connor; Joseph G Hentz; Marwan N Sabbagh; John N Caviness; Holly A Shill; Brie Noble; Thomas G Beach
Journal:  Mov Disord       Date:  2010-04-15       Impact factor: 10.338

4.  Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients.

Authors:  Jiguang Guo; Zhongwu Sun; Shifu Xiao; Dongping Liu; Guohua Jin; Ersong Wang; Jiangning Zhou; Jiawei Zhou
Journal:  Cell Res       Date:  2009-12-01       Impact factor: 25.617

Review 5.  Transthyretin: more than meets the eye.

Authors:  Carolina Estima Fleming; Ana Filipa Nunes; Mónica Mendes Sousa
Journal:  Prog Neurobiol       Date:  2009-08-07       Impact factor: 11.685

6.  A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

Authors:  C E Teunissen; A Petzold; J L Bennett; F S Berven; L Brundin; M Comabella; D Franciotta; J L Frederiksen; J O Fleming; R Furlan; R Q Hintzen; S G Hughes; M H Johnson; E Krasulova; J Kuhle; M C Magnone; C Rajda; K Rejdak; H K Schmidt; V van Pesch; E Waubant; C Wolf; G Giovannoni; B Hemmer; H Tumani; F Deisenhammer
Journal:  Neurology       Date:  2009-12-01       Impact factor: 9.910

7.  Association of fibrinogen with Parkinson disease in elderly Japanese-American men: a prospective study.

Authors:  K T Wong; J S Grove; A Grandinetti; J D Curb; M Yee; P Blanchette; G W Ross; B I Rodriguez
Journal:  Neuroepidemiology       Date:  2009-11-21       Impact factor: 3.282

8.  Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease.

Authors:  Alex E Roher; Chera L Maarouf; Lucia I Sue; Yiran Hu; Jeffrey Wilson; Thomas G Beach
Journal:  Biomarkers       Date:  2009-11       Impact factor: 2.658

Review 9.  Chapter 8: Clusterin: A multifacet protein at the crossroad of inflammation and autoimmunity.

Authors:  Géraldine Falgarone; Gilles Chiocchia
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

10.  Chapter 1: Introduction.

Authors:  Saverio Bettuzzi
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

View more
  21 in total

1.  Submandibular gland needle biopsy for the diagnosis of Parkinson disease.

Authors:  Charles H Adler; Brittany N Dugger; Michael L Hinni; David G Lott; Erika Driver-Dunckley; Jose Hidalgo; Jonette Henry-Watson; Geidy Serrano; Lucia I Sue; Thomas Nagel; Amy Duffy; Holly A Shill; Haruhiko Akiyama; Douglas G Walker; Thomas G Beach
Journal:  Neurology       Date:  2014-02-05       Impact factor: 9.910

2.  Variations in the cerebrospinal fluid proteome following traumatic brain injury and subarachnoid hemorrhage.

Authors:  David E Connor; Ganta V Chaitanya; Prashant Chittiboina; Paul McCarthy; L Keith Scott; Lisa Schrott; Alireza Minagar; Anil Nanda; J Steven Alexander
Journal:  Pathophysiology       Date:  2017-05-13

3.  Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease.

Authors:  Yue Yang; C Dirk Keene; Elaine R Peskind; Douglas R Galasko; Shu-Ching Hu; Eiron Cudaback; Angela M Wilson; Ge Li; Chang-En Yu; Kathleen S Montine; Jing Zhang; Geoffrey S Baird; Bradley T Hyman; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2015-07       Impact factor: 3.685

4.  Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.

Authors:  Thomas G Beach; Charles H Adler; Lucia I Sue; Geidy Serrano; Holly A Shill; Douglas G Walker; LihFen Lue; Alex E Roher; Brittany N Dugger; Chera Maarouf; Alex C Birdsill; Anthony Intorcia; Megan Saxon-Labelle; Joel Pullen; Alexander Scroggins; Jessica Filon; Sarah Scott; Brittany Hoffman; Angelica Garcia; John N Caviness; Joseph G Hentz; Erika Driver-Dunckley; Sandra A Jacobson; Kathryn J Davis; Christine M Belden; Kathy E Long; Michael Malek-Ahmadi; Jessica J Powell; Lisa D Gale; Lisa R Nicholson; Richard J Caselli; Bryan K Woodruff; Steven Z Rapscak; Geoffrey L Ahern; Jiong Shi; Anna D Burke; Eric M Reiman; Marwan N Sabbagh
Journal:  Neuropathology       Date:  2015-01-26       Impact factor: 1.906

Review 5.  Glutathione metabolism and Parkinson's disease.

Authors:  Michelle Smeyne; Richard Jay Smeyne
Journal:  Free Radic Biol Med       Date:  2013-05-08       Impact factor: 7.376

6.  Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype.

Authors:  Christine R Swanson; Katherine Li; Travis L Unger; Michael D Gallagher; Vivianna M Van Deerlin; Pinky Agarwal; James Leverenz; John Roberts; Ali Samii; Rachel Goldmann Gross; Howard Hurtig; Jacqueline Rick; Daniel Weintraub; John Q Trojanowski; Cyrus Zabetian; Alice S Chen-Plotkin
Journal:  Mov Disord       Date:  2014-09-16       Impact factor: 10.338

7.  Specific changes of serum proteins in Parkinson's disease patients.

Authors:  Wenwen Lu; Xinhua Wan; Bin Liu; Xianfang Rong; Lei Zhu; Pingping Li; Jiang Li; Ling Wang; Liying Cui; Xiaoliang Wang
Journal:  PLoS One       Date:  2014-04-25       Impact factor: 3.240

8.  Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology.

Authors:  Kasandra Burgos; Ivana Malenica; Raghu Metpally; Amanda Courtright; Benjamin Rakela; Thomas Beach; Holly Shill; Charles Adler; Marwan Sabbagh; Stephen Villa; Waibhav Tembe; David Craig; Kendall Van Keuren-Jensen
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

Review 9.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

10.  Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology.

Authors:  Chera L Maarouf; Thomas G Beach; Charles H Adler; Michael Malek-Ahmadi; Tyler A Kokjohn; Brittany N Dugger; Douglas G Walker; Holly A Shill; Sandra A Jacobson; Marwan N Sabbagh; Alex E Roher
Journal:  Biomark Insights       Date:  2013-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.